SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cancer Incidence in Five Continents, Vol IX. IARC Scientific Publications no 160. Lyon: International Agency for Research on Cancer; 2008.
  • 2
    Bouchardy C, Neyroud-Caspar I, Keller Mighali J, Usel M. Le Cancer a Geneve –Incidence, Mortalite, Survie et Prevalence 2003-2006. http://asrt.ch/rgt/publication_1970_2006.pdf. Accessed February 24, 2010.
  • 3
    Dougherty SM, Mazhawidza W, Bohn AR, et al. Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocr Relat Cancer. 2006; 13: 113134.
  • 4
    Ivanova MM, Mazhawidza W, Dougherty SM, Minna JD, Klinge CM. Activity and intracellular location of estrogen receptors alpha and beta in human bronchial epithelial cells. Mol Cell Endocrinol. 2009; 305: 1221.
  • 5
    Dubey S, Siegfried JM, Traynor AM. Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. Lancet Oncol. 2006; 7: 416424.
  • 6
    Niikawa H, Suzuki T, Miki Y, et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res. 2008; 14: 44174426.
  • 7
    Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. 2005; 65: 14591470.
  • 8
    Stabile LP, Davis AL, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res. 2002; 62: 21412150.
  • 9
    Slatore CG, Chien JW, Au DH, Satia JA, White E. Lung cancer and hormone replacement therapy: association in the Vitamins and Lifestyle Study. J Clin Oncol. 2010; 28: 15401546.
  • 10
    Liu Y, Inoue M, Sobue T, Tsugane S. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer. 2005; 117: 662666.
  • 11
    Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer. 1989; 44: 833839.
  • 12
    Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst. 1994; 86: 869870.
  • 13
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321333.
  • 14
    Kreuzer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann HE. Hormonal factors and risk of lung cancer among women? Int J Epidemiol. 2003; 32: 263271.
  • 15
    Olsson H, Bladstrom A, Ingvar C. Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy? Obstet Gynecol. 2003; 102: 565570.
  • 16
    Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res. 2004; 10: 113123.
  • 17
    Schwartz AG, Wenzlaff AS, Prysak GM, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol. 2007; 25: 57855792.
  • 18
    Chen KY, Hsiao CF, Chang GC, et al. Hormone replacement therapy and lung cancer risk in Chinese. Cancer. 2007; 110: 17681775.
  • 19
    Baik CS, Strauss GM, Speizer FE, Feskanich D. Reproductive factors, hormone use, and risk for lung cancer in postmenopausal women, the nurses' health study. Cancer Epidemiol Biomarkers Prev. In press.
  • 20
    Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet. 2009; 374: 12431251.
  • 21
    Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol. 2006; 24: 5963.
  • 22
    Chlebowski RT, Anderson GL, Manson JE, et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst 2010; 102: 14131421.
  • 23
    Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol. 1996; 87: 612.
  • 24
    Ayeni O, Robinson A. Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed? Curr Oncol. 2009; 16: 21-25.
  • 25
    Huang B, Carloss H, Wyatt SW, Riley E. Hormone replacement therapy and survival in lung cancer in postmenopausal women in a rural population. Cancer. 2009; 115: 41674175.
  • 26
    Fritz A, Percy C, Jack A, et al. eds. ICD-O International Classification of Diseases for Oncology, 3rd Edition. Geneva: World Health Organization; 2000.
  • 27
    World Health Organization (WHO), eds. ICD-10. International Statistical Classification of Diseases and Health Related Problems, 10th Revision. Geneva: World Health Organization; 1992.
  • 28
    Sobin LH, Wittekind Ch, eds. TNM Classification Of Malignant Tumours, 6th Edition. New York: UICC; 2002.
  • 29
    Breslow NE, Day NE. Statistical Methods in Cancer Res. Vol I: The Analysis of Case-Control Studies. IARC Scientific Publications no 32. Lyon: International Agency for Research on Cancer; 1980.
  • 30
    Keller R, Kutter, B., Krebs H, Hornung R. Tabakmonitoring. Bericht uber den Tabakkonsum der Schweizer Wohnbevolkerung in den Jahren 2001 und 2002. Zurich: Psychologisches Institut der Universitat Zurich, Sozialpsychologie II; 2003.
  • 31
    Patel JD, Gray RG, Stewart JA, Skinner HG, Schiller JH. Tamoxifen does not reduce the risk of lung cancer in women. Available at: http://www.asco.org/ASCOv2/Meetings/Abstracts? &vmview=abst_detail_view&confID=34&abstractID=32861. Accessed July 1, 2009.
  • 32
    Raso MG, Behrens C, Herynk MH, et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 2009; 15: 53595368.
  • 33
    Weinberg OK, Marquez-Garban DC, Fishbein MC, et al. Aromatase inhibitors in human lung cancer therapy. Cancer Res. 2005; 65: 1128711291.
  • 34
    Mah V, Seligson DB, Li A, et al. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res. 2007; 67: 1048410490.
  • 35
    Cote ML, Yoo W, Wenzlaff AS, et al. Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women. Carcinogenesis. 2009; 30: 626635.